Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
Top Page
Sagimet Biosciences, Inc. Class A
(NASDAQ:SGMT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$5.50
▼(-2.48% Downside)
Action:ReiteratedDate:03/24/26
The score is held back primarily by weak financial performance (persistent losses, minimal revenue, and significant cash burn) and bearish technical trend signals. Offsetting these risks are a low-debt, currently positive-equity balance sheet and constructive clinical/regulatory progress from recent corporate updates.
Positive Factors
Low Leverage & Positive Equity
Very low reported debt and recent positive equity positions provide durable financial flexibility for a development-stage biotech. This reduces near-term refinancing/default risk, enabling continued R&D investment and partnering without immediate solvency pressure, a lasting structural strength over months.
Negative Factors
Rising Cash Burn
Cash burn has accelerated year-over-year, reflecting intensified development spending. Persistently negative operating and free cash flow will likely force new financing within the medium term unless offset by partnerships or revenue, creating dilution risk and constraining strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage & Positive Equity
Very low reported debt and recent positive equity positions provide durable financial flexibility for a development-stage biotech. This reduces near-term refinancing/default risk, enabling continued R&D investment and partnering without immediate solvency pressure, a lasting structural strength over months.
Read all positive factors
Sagimet Biosciences, Inc. Class A (SGMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$180.58M
Dividend YieldN/A
Average Volume (3M)335.19K
Price to Earnings (P/E)―
Beta (1Y)2.85
Revenue GrowthN/A
EPS Growth-38.23%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding32,017,612
10 Day Avg. Volume375,133
30 Day Avg. Volume335,186
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$26.22Price Target Upside364.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$300.00K
Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidat...
How the Company Makes Money
Sagimet Biosciences primarily makes money through the development and commercialization of its drug candidates. Revenue streams are potentially derived from partnerships, licensing agreements, and collaborations with larger pharmaceutical companie...
Sagimet Biosciences, Inc. Class A Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| EBITDA | -56.89M | -45.57M | -30.74M | -31.05M | -23.72M |
| Net Income | -51.04M | -45.57M | -27.88M | -30.50M | -24.44M |
Balance Sheet | |||||
| Total Assets | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M |
| Cash, Cash Equivalents and Short-Term Investments | 113.12M | 151.25M | 94.90M | 32.34M | 56.73M |
| Total Debt | 78.00K | 78.00K | 65.00K | 211.00K | 348.00K |
| Total Liabilities | 5.10M | 4.45M | 5.65M | 219.98M | 217.29M |
| Stockholders Equity | 111.38M | 155.81M | 91.06M | -186.95M | -158.26M |
Cash Flow | |||||
| Free Cash Flow | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Operating Cash Flow | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Investing Cash Flow | 4.56M | -61.68M | 12.58M | -32.01M | 0.00 |
| Financing Cash Flow | 275.00K | 104.82M | 86.17M | -73.00K | 9.74M |
Sagimet Biosciences, Inc. Class A Technical Analysis
Neutral
5.64
Price Trends
5.38
Positive
5.89
Negative
6.97
Negative
Market Momentum
>-0.01
Negative
57.72
Neutral
85.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Neutral. The current price of 5.64 is above the 20-day moving average (MA) of 5.07, above the 50-day MA of 5.38, and below the 200-day MA of 6.97, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.72 is Neutral, neither overbought nor oversold. The STOCH value of 85.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SGMT.
Sagimet Biosciences, Inc. Class A Risk Analysis
Sagimet Biosciences, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Sagimet Biosciences, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sagimet Biosciences, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $465.29M | -1.84 | -46.34% | ― | ― | 14.33% | |
55 Neutral | $537.89M | -2.96 | -39.83% | ― | -71.42% | -248.91% | |
52 Neutral | $147.80M | 6.18 | 17.46% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $180.58M | -3.75 | -40.85% | ― | ― | -38.23% | |
50 Neutral | $218.09M | -3.23 | -90.51% | ― | -17.87% | 14.42% | |
50 Neutral | $352.89M | -1.34 | -121.73% | ― | ― | -17.21% |
* Healthcare Sector Average
SGMT
Sagimet Biosciences, Inc. Class A
5.64
3.41
152.91%
CDXS
Codexis
2.40
0.15
6.67%
CABA
Cabaletta Bio
3.17
2.08
190.83%
BDTX
Black Diamond Therapeutics
2.58
1.16
81.69%
AVIR
Atea Pharmaceuticals
5.84
3.15
117.10%
TRDA
Entrada Therapeutics Inc
14.05
6.20
78.98%
Sagimet Biosciences, Inc. Class A Corporate Events
Business Operations and StrategyFinancial Disclosures
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress
Positive
Mar 11, 2026
Sagimet Biosciences reported its fourth-quarter and full-year 2025 results on March 11, 2026, highlighting clinical progress across its MASH and acne portfolios and solid liquidity of $113.1 million in cash, cash equivalents and marketable securit...
Business Operations and StrategyProduct-Related Announcements
Sagimet Biosciences Reports Positive Phase 3 Acne Data
Positive
Feb 2, 2026
On February 2, 2026, Sagimet Biosciences reported that its Chinese license partner Ascletis Pharma released positive topline data from a 52-week Phase 3 program of denifanstat (ASC40) in patients with moderate to severe acne, including an open-lab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.